Your browser doesn't support javascript.
loading
Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice.
Isidro-Hernández, Marta; Casado-García, Ana; Oak, Ninad; Alemán-Arteaga, Silvia; Ruiz-Corzo, Belén; Martínez-Cano, Jorge; Mayado, Andrea; Sánchez, Elena G; Blanco, Oscar; Gaspar, Ma Luisa; Orfao, Alberto; Alonso-López, Diego; De Las Rivas, Javier; Riesco, Susana; Prieto-Matos, Pablo; González-Murillo, África; Criado, Francisco Javier García; Cenador, María Begoña García; Ramírez-Orellana, Manuel; de Andrés, Belén; Vicente-Dueñas, Carolina; Cobaleda, César; Nichols, Kim E; Sánchez-García, Isidro.
Affiliation
  • Isidro-Hernández M; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Casado-García A; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Oak N; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Alemán-Arteaga S; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Ruiz-Corzo B; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Martínez-Cano J; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Mayado A; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Sánchez EG; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, Salamanca, Spain.
  • Blanco O; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Gaspar ML; Immune system development and function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid), Madrid, Spain.
  • Orfao A; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Alonso-López D; Servicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Salamanca, Spain.
  • De Las Rivas J; Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.
  • Riesco S; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Prieto-Matos P; Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.
  • González-Murillo Á; Immunobiology Department, Carlos III Health Institute, 28220, Majadahonda (Madrid), Spain.
  • Criado FJG; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Cenador MBG; Servicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Salamanca, Spain.
  • Ramírez-Orellana M; Bioinformatics Unit, Cancer Research Center (CSIC-USAL), Salamanca, Spain.
  • de Andrés B; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Vicente-Dueñas C; Bioinformatics and Functional Genomics Research Group, Cancer Research Center (CSIC-USAL), Salamanca, Spain.
  • Cobaleda C; Department of Pediatrics, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain.
  • Nichols KE; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
  • Sánchez-García I; Department of Pediatrics, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain.
Nat Commun ; 14(1): 5159, 2023 08 24.
Article in En | MEDLINE | ID: mdl-37620322
ABSTRACT
The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5+/- B-cell precursors toward leukemia. Transcriptional profiling reveals that Myd88 is downregulated in immune-stressed pre-malignant B-cell precursors and in leukemic cells. Genetic reduction of Myd88 expression leads to a significant increase in leukemia incidence in Pax5+/-Myd88+/- mice through an inflammation-dependent mechanism. Early induction of Myd88-independent Toll-like receptor 3 signaling results in a significant delay of leukemia development in Pax5+/- mice. Altogether, these findings identify a role for innate immunity dysregulation in leukemia, with important implications for understanding and therapeutic targeting of the preleukemic state in children.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Leukemia / Burkitt Lymphoma Type of study: Prognostic_studies Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Leukemia / Burkitt Lymphoma Type of study: Prognostic_studies Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country:
...